Moderna to seek FDA approval for COVID-19 vaccines for children under 6
"Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible," Chief Executive Stéphane Bancel said in a statement
By Arghyadeep Dutta
Published - Mar 23, 2022, 08:15 PM ET
Last Updated - Feb 21, 2024, 03:06 AM EST
• Children were only given 25% of vaccines that were given to adults
• Although the efficacy rate is below 45%, no severe cases of COVID-19 were reported in the trial
On Wednesday, Moderna Inc (NASDAQ: MRNA) said it will seek U.S. Food and Drug Administration (FDA) authorization for its COVID-19 vaccine for children between 6 months and 6 years old.
"Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible," Chief Executive Stéphane Bancel said in a statement.
